Esperion Therapeutics (ESPR) Tops Q2 EPS by $2.61, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update
August 10, 2020 4:05 PM EDT Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue
 Strong Capital Position with over $300 Million in Cash
 Extraordinary High-Quality Managed Care Coverage with Over 80% Commercial and Over 50% Medicare Part D Formulary Coverage
 Consistently High Month-Over-Month Growth for New Medicines With Acceleration in Second Half
 Conference Call and Webcast on August 10 at 4:30 P.M. Eastern Time
ANN ARBOR, Mich., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results... More
